Propofol injectable emulsion is indicated for induction of general anesthesia in patients aged 3 years or older, maintenance of general anesthesia in patients aged 2 months or older, and for monitored anesthesia care (MAC) sedation in adult patients. It is also used for sedation in combination with regional anesthesia and intensive care unit (ICU) sedation of intubated, mechanically ventilated adult patients.
Pediatric Dosage Studies
Studies involving pediatric patients aged 3 years or older demonstrated induction doses ranging from 1 mg/kg to 3.6 mg/kg with injection durations of 6 to 45 seconds. Maintenance dosages varied depending on age, with ranges of 82 to 394 mcg/kg/min for patients 2 months to 2 years and 12 to 1041 mcg/kg/min for patients 2 to 12 years.
Clinical Trial Data
In clinical trials for craniotomy patients, propofol was administered at a median dose of 1.4 mg/kg for induction and 146 mcg/kg/min for maintenance. The emulsion’s mechanism of action involves positive modulation of GABA A receptors. Hemodynamic effects vary, with hypotension observed during induction, particularly when assisted ventilation is used. The product is packaged under nitrogen and should be inspected for particulate matter or discoloration before administration. Continuous monitoring is required during use.